DE69730093D1 - Zubereitung mit verzögerter Freisetzung - Google Patents

Zubereitung mit verzögerter Freisetzung

Info

Publication number
DE69730093D1
DE69730093D1 DE69730093T DE69730093T DE69730093D1 DE 69730093 D1 DE69730093 D1 DE 69730093D1 DE 69730093 T DE69730093 T DE 69730093T DE 69730093 T DE69730093 T DE 69730093T DE 69730093 D1 DE69730093 D1 DE 69730093D1
Authority
DE
Germany
Prior art keywords
release preparation
active substance
physiologically active
delayed release
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730093T
Other languages
English (en)
Other versions
DE69730093T2 (de
Inventor
Hiroaki Okada
Yayoi Douken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69730093D1 publication Critical patent/DE69730093D1/de
Publication of DE69730093T2 publication Critical patent/DE69730093T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69730093T 1996-10-31 1997-10-30 Zubereitung mit verzögerter Freisetzung Expired - Lifetime DE69730093T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29044196 1996-10-31
JP29044196 1996-10-31

Publications (2)

Publication Number Publication Date
DE69730093D1 true DE69730093D1 (de) 2004-09-09
DE69730093T2 DE69730093T2 (de) 2006-07-20

Family

ID=17756079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730093T Expired - Lifetime DE69730093T2 (de) 1996-10-31 1997-10-30 Zubereitung mit verzögerter Freisetzung

Country Status (9)

Country Link
US (2) US6113943A (de)
EP (1) EP0839525B1 (de)
JP (1) JP4361144B2 (de)
AT (1) ATE272394T1 (de)
CA (1) CA2219698C (de)
DE (1) DE69730093T2 (de)
DK (1) DK0839525T3 (de)
ES (1) ES2221019T3 (de)
PT (1) PT839525E (de)

Families Citing this family (350)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
EP0998940A1 (de) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmazeutische zusammensetzung basierend auf alpha-cyclodextrin für die orale verabreichung von LH-RH analogen
DE69923795T2 (de) 1998-12-15 2006-03-16 Takeda Pharmaceutical Co. Ltd. Verfahren zur Herstellung biologisch-abbaubarer Polyester
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
NZ516466A (en) 1999-07-15 2003-02-28 Takeda Chemical Industries Ltd Sustained release compositions, process for producing the same and use thereof
US6303138B1 (en) * 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
EP1274459B1 (de) 2000-04-19 2005-11-16 Genentech, Inc. Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
CA2407235A1 (en) * 2000-04-28 2001-11-08 Fziomed, Inc. Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
ATE322513T1 (de) 2000-08-07 2006-04-15 Wako Pure Chem Ind Ltd Milchsäurepolymer und verfahren zu dessen herstellung
AU2002232824A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DK1372729T3 (da) * 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
CA2444727A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Agents for preventing postoperative recurrence of premenopausal breast cancer
US7318931B2 (en) * 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
DE60231549D1 (de) * 2001-12-03 2009-04-23 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
JP2003192773A (ja) * 2001-12-26 2003-07-09 Mitsui Chemicals Inc 生体吸収性ポリヒドロキシカルボン酸及びその製造法
AU2003211877A1 (en) * 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
DK1532985T3 (en) 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
EP1622540A4 (de) * 2003-03-11 2009-12-30 Qlt Usa Inc Formulierungen für zellen-plan-abhängige krebsmittel
EP1620060B1 (de) * 2003-04-29 2010-03-24 The General Hospital Corporation Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20040244806A1 (en) * 2003-06-09 2004-12-09 Ferree Bret A. Treating disc herniation and other conditions with leukocytes
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
ES2336913T3 (es) 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US8846069B2 (en) * 2003-11-20 2014-09-30 Abbott Cardiovascular Systems Inc. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20060094651A1 (en) * 2004-11-03 2006-05-04 Cyrus Karkaria Formulations and methods of production of FGF-20
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
WO2005122734A2 (en) * 2004-06-14 2005-12-29 The Research Foundation Of State University Of New York Nanosphere/microsphere delivery system for the treatment of spinal cord injury
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8920782B2 (en) * 2005-01-14 2014-12-30 Camurus Ab Topical bioadhesive formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2006137953A1 (en) 2005-04-01 2006-12-28 The Regents Of The Univerisity Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
DE602006000381T2 (de) * 2005-04-28 2008-12-18 Nipro Corp., Osaka Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
JP5198261B2 (ja) * 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
WO2007029361A1 (ja) * 2005-09-02 2007-03-15 Takeda Pharmaceutical Company Limited 短鎖デオキシリボ核酸又は短鎖リボ核酸含有徐放性マイクロスフェア及びその製造法
EP1787658B1 (de) 2005-11-10 2012-03-14 CHEMI S.p.A. Formulierungen mit verzögerter Freisetzung, die Somatostatin-analoge Wachstumshormoninhibitoren enthalten
RU2457854C2 (ru) 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Длительное высвобождение нейрегулина для улучшения сердечной функции
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
CN101443314B (zh) * 2006-03-13 2014-04-09 杏林制药株式会社 作为gsk-3抑制剂的氨基喹诺酮类
AU2007225207A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
WO2008036379A2 (en) 2006-09-21 2008-03-27 Activx Biosciences, Inc. Serine hydrolase inhibitors
ATE502921T1 (de) 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
WO2008075762A1 (en) 2006-12-18 2008-06-26 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
ATE525068T1 (de) 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
EP3269706A1 (de) 2007-03-15 2018-01-17 Auspex Pharmaceuticals, Inc. Substituiertes phenethylamin mit serotoninergischer und/oder norepinephrinergischer aktivität
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
EP2170062A4 (de) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von krebserkrankungen, tumoren und tumorvermittelten erkrankungen
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
JP5426552B2 (ja) * 2007-09-11 2014-02-26 杏林製薬株式会社 Ｇｓｋ−３阻害剤としてのシアノアミノキノロン及びテトラゾロアミノキノロン
MX2010002662A (es) 2007-09-12 2010-04-09 Activx Biosciences Inc Aminoquinolonas espirociclicas como inhibidores de gsk-3.
ES2528409T3 (es) 2007-10-24 2015-02-10 Camurus Ab Formulaciones de liberación controlada
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
HUE032873T2 (en) 2008-03-17 2017-11-28 Ambit Biosciences Corp 1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
JP2011521915A (ja) * 2008-05-20 2011-07-28 セレニス セラピューティクス エス．エー． ナイアシン及びｎｓａｉｄ併用療法
EP2476690A1 (de) 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Verbindungen und pharmazeutische Zusammensetzungen für die Behandlung von Virusinfektionen
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
AU2009324545A1 (en) * 2008-12-11 2011-06-30 A.P. Pharma, Inc. Methods for enhancing stability of polyorthoesters and their formulations
JP5780969B2 (ja) 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
EP2601934A1 (de) 2009-01-22 2013-06-12 Ludwig-Maximilians-Universität München Vesikuläre Phospholipid-Gele mit proteinösen Substanzen
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AR075633A1 (es) 2009-02-27 2011-04-20 Ambit Biosciences Corp Compuestos moduladores de jak quinasa y sus metodos de uso
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
WO2010104205A1 (en) * 2009-03-11 2010-09-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
EP2411387B1 (de) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl- und 1,3,5-triazinyl-benzimidazol-sulfonamide und ihre verwendung in der krebstherapie
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
ES2474615T3 (es) 2009-04-22 2014-07-09 Axikin Pharmaceuticals, Inc. Antagonistas de CCR3 arilsulfonamidas 2,5-disustituidas
JP2012524789A (ja) 2009-04-22 2012-10-18 アクシキン ファーマシューティカルズ インコーポレーテッド ２，５−二置換アリールスルホンアミドｃｃｒ３アンタゴニスト
US8420639B2 (en) 2009-04-22 2013-04-16 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (de) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl- und 1,3,5-triazinyl-benzimidazole und ihre verwendung in der krebstherapie
AU2010270605B2 (en) 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CA2770454A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
JP2013516424A (ja) 2009-12-30 2013-05-13 サイネクシス，インコーポレーテッド シクロスポリン類似体
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
ES2632548T3 (es) 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
RS58523B1 (sr) 2010-02-11 2019-04-30 Celgene Corp Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
ES2542404T3 (es) 2010-03-02 2015-08-05 Axikin Pharmaceuticals, Inc. Antagonistas de CCR3 de tipo arilsulfonamida enriquecidos isotópicamente
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
AU2011227232B2 (en) 2010-03-17 2015-07-09 Axikin Pharmaceuticals Inc. Arylsulfonamide CCR3 antagonists
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
JP5844354B2 (ja) 2010-06-01 2016-01-13 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
CN103153309A (zh) 2010-06-01 2013-06-12 拜欧赛里克斯公司 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
MX2012014273A (es) 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
EP2595615A1 (de) 2010-07-19 2013-05-29 Summa Health System Vitamin c und chromfreies vitamin k sowie zusammensetzungen daraus zur behandlung von nfkb-induzierten leiden oder erkrankungen
AU2011296046B2 (en) 2010-09-01 2015-05-14 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US20130225614A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611502A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosin-a3-rezeptormodulierende verbindungen und ihre verwendung
EP2611789A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Chinazolinverbindungen und anwendungsverfahren dafür
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
ES2579942T3 (es) 2010-09-01 2016-08-17 Ambit Biosciences Corporation Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611793A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cyclochinazolinderivate und verwendungsverfahren dafür
EP2611448A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylchinazolinderivate und verwendungsverfahren dafür
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
EP2637669A4 (de) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclische verbindungen und ihre verwendung
BR112013014021A8 (pt) 2010-12-06 2017-10-03 Follica Inc Métodos para tratamento de calvície e promoção de crescimento de cabelos
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
JP2014501790A (ja) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノンの調製方法及びイソキノリノンの固体形態
MX2013006020A (es) 2011-01-31 2013-10-01 Celgene Corp Composicion farmaceutica de analogos de citidina y metodos para su uso.
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
CN103561744A (zh) 2011-03-11 2014-02-05 细胞基因公司 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮在治疗免疫相关性和炎症性疾病中的用途
JP2014509648A (ja) 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
EP2691388A1 (de) 2011-03-28 2014-02-05 MEI Pharma, Inc. (kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
EP2691409B1 (de) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
WO2013003157A1 (en) 2011-06-28 2013-01-03 Yale University Cell-free tissued engineered vascular grafts
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013056070A2 (en) 2011-10-14 2013-04-18 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
EP2768838A1 (de) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituierte 3 ', 5 '-cyclophosphate von purin-nukleotid-verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
US8586527B2 (en) 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
SI2787974T1 (sl) 2011-12-05 2017-10-30 Camurus Ab Robustno kontrolirano-sproščujoče peptidne formulacije
EP2793580A4 (de) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc Neuartige isoergolinderivate
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
RU2014141674A (ru) 2012-03-16 2016-05-10 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
AU2013265210B2 (en) 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
AU2013271731A1 (en) 2012-06-07 2014-12-18 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
ES2800026T3 (es) 2012-08-09 2020-12-23 Celgene Corp Tratamiento de enfermedades inmunitarias e inflamatorias
MX359508B (es) 2012-08-09 2018-09-28 Celgene Corp Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2,6-diona y composiciones que comprenden y metodos para utilizar las mismas.
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
RU2015112605A (ru) 2012-09-07 2016-10-27 Аксикин Фармасьютикалз, Инк. Изотопно-обогащенные арилсульфонамидные антагонисты ccr3
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
EP2909223B1 (de) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinukleotidverbindungen für hcv-infektion
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
CA2890177A1 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
EP2938624A1 (de) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. D-alaninester von sp-nukleosidanalogon
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP3447046A1 (de) 2012-11-30 2019-02-27 Novomedix, LLC Substituierte biarylsulfonamide und verwendung davon
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
SG11201504931SA (en) 2012-12-21 2015-07-30 Map Pharmaceuticals Inc Novel methysergide derivatives
WO2014110305A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
EP2970358B1 (de) 2013-03-04 2021-06-30 Idenix Pharmaceuticals LLC 3'-deoxy-nukleoside zur behandlung von hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CA2922230A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (de) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibitoren des hepatitis-c-virus
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
MX2016006919A (es) 2013-11-27 2016-08-17 Idenix Pharmaceuticals Llc Nucleotidos para el tratamiento de cancer de higado.
EP3083654A1 (de) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or-nukleoside zur behandlung von hcv
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
AU2015231215B2 (en) 2014-03-20 2019-07-18 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
RU2021101430A (ru) 2014-03-20 2021-03-16 Капелла Терапьютикс, Инк. Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP3129381B1 (de) 2014-04-09 2020-11-04 Siteone Therapeutics Inc. Zur behandlung von schmerz geeignete 10',11'-modifizierte saxitonine
EP3131914B1 (de) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3142649B1 (de) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Behandlung der komplikationen von chronischer lebererkrankung mit caspase-inhibitor emricasan
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
MA40240B1 (fr) 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3191100A4 (de) 2014-09-12 2018-05-30 Tobira Therapeutics, Inc. Cenicriviroc-kombinationstherapie zur behandlung von fibrose
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR102331856B1 (ko) 2014-10-21 2021-11-29 다케다 야쿠힌 고교 가부시키가이샤 결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
KR102034202B1 (ko) 2014-12-23 2019-10-18 에스엠에이 세라퓨틱스 아이엔씨. 3,5-디아미노피라졸 키나제 억제제
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
US10815264B2 (en) 2015-05-27 2020-10-27 Southern Research Institute Nucleotides for the treatment of cancer
KR20180015260A (ko) 2015-06-23 2018-02-12 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
CA2985123C (en) 2015-08-17 2021-04-13 Antonio Gualberto Methods of treating cancer patients with farnesyltransferase inhibitors
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
AU2016343633B2 (en) 2015-10-30 2021-07-01 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
WO2017112857A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
SG11201805480TA (en) 2015-12-31 2018-07-30 Conatus Pharmaceuticals Inc Methods of using caspase inhibitors in treatment of liver disease
ES2832475T3 (es) 2016-01-08 2021-06-10 Celgene Corp Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
WO2017120446A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2019513707A (ja) 2016-04-11 2019-05-30 クレキシオ バイオサイエンシーズ エルティーディー． 重水素化ケタミン誘導体
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN110072861B (zh) 2016-09-07 2022-11-11 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
MY190861A (en) 2016-11-03 2022-05-12 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer
CA3042055A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
MX2020003462A (es) 2017-01-27 2020-08-03 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2019009821A (es) 2017-02-21 2019-12-02 Kura Oncology Inc Metodos para tratar cancer con inhibidores de farnesiltransferasa.
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
EP3601326A4 (de) 2017-03-20 2020-12-16 The Broad Institute, Inc. Verbindungen und verfahren zur regulierung der insulinsekretion
CN110799192A (zh) 2017-03-27 2020-02-14 加利福尼亚大学董事会 治疗癌症的组合物和方法
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3058214A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3063535A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
WO2018213810A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
EP3658187A1 (de) 2017-07-27 2020-06-03 Allergan, Inc. Prostacyclinrezeptor-agonisten zur reduktion von körperfett
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
BR112020002591A2 (pt) 2017-08-07 2020-07-28 Kura Oncology, Inc. método para o tratamento de câncer
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
EP3691658A4 (de) 2017-10-04 2021-06-23 The Regents of The University of California Immunmodulatorische oligosaccharide
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW201929847A (zh) 2018-01-10 2019-08-01 美商克拉治療有限責任公司 包含二羧酸之醫藥組合物及其治療應用
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
MA52896A (fr) 2018-06-14 2021-04-21 Neurocrine Biosciences Inc Composés inhibiteurs de vmat2, compositions et méthodes associées
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
EP3836926A4 (de) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Verfahren zur verabreichung bestimmter vmat2-inhibitoren
EP3860714B1 (de) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modifizierte saxitoxine zur behandlung von schmerzen
CN113286591A (zh) 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
WO2020106303A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
EP4233834A3 (de) 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Aryl-anilin- und heteroaryl-anilinverbindungen zur behandlung von muttermalen
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
US20230078755A1 (en) 2018-12-19 2023-03-16 Shy Therapeutics, Llc Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
JP2022514654A (ja) 2018-12-21 2022-02-14 クラ オンコロジー， インコーポレイテッド 扁平上皮癌のための治療法
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3132613A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202043487A (zh) 2019-03-29 2020-12-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
US20220274922A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
US20220274921A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
TW202118750A (zh) 2019-07-26 2021-05-16 美商艾斯佩維他治療學公司 官能化的長鏈烴一元及二元羧酸及其用於預防或治療疾病的用途
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2020342591A1 (en) 2019-09-02 2022-03-03 Camurus Ab Formulations and treatment methods
EP4031534A1 (de) 2019-09-16 2022-07-27 Dice Alpha, Inc. Il-17a-modulatoren und verwendungen davon
EP4034236A1 (de) 2019-09-26 2022-08-03 Abionyx Pharma SA Verbindungen zur behandlung von lebererkrankungen
US11643420B2 (en) 2019-10-01 2023-05-09 Molecular Skin Therapeutics, Inc. Benzoxazinone compounds as KLK5/7 dual inhibitors
JP2021147329A (ja) * 2020-03-16 2021-09-27 株式会社リコー 粒子の製造方法
CA3179635A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4149471A4 (de) 2020-06-30 2024-07-10 Prosetta Biosciences Inc Isochinolinderivate, verfahren zur synthese und verwendungen davon
CA3188924A1 (en) 2020-08-14 2022-02-17 Hassan Pajouhesh Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
EP4284377A1 (de) 2021-01-27 2023-12-06 Shy Therapeutics LLC Verfahren zur behandlung von fibrotischen erkrankungen
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
EP4402124A1 (de) 2021-10-22 2024-07-24 Prosetta Biosciences, Inc. Neue wirtsgerichtete pan-respiratorische antivirale kleinmolekül-therapeutika
AU2022399572A1 (en) 2021-11-30 2024-05-02 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
CN114404663A (zh) * 2022-01-07 2022-04-29 浙江瑞谷生物科技有限公司 一种具有炎症缓解特性的骨修复材料及其制备方法
CN114404664A (zh) * 2022-02-17 2022-04-29 浙江瑞谷生物科技有限公司 一种具备长效缓释的骨修复支架材料及其制备方法及应用
WO2023192817A1 (en) 2022-03-28 2023-10-05 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230348909A1 (en) 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AR129053A1 (es) 2022-04-14 2024-07-10 Bristol Myers Squibb Co Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
TW202406557A (zh) 2022-05-05 2024-02-16 美商拜奧馬林製藥公司 治療杜興氏肌肉失養症之方法
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
US20240139187A1 (en) 2022-10-12 2024-05-02 The Children's Medical Center Corporation Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024145662A1 (en) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5183662A (en) 1990-08-30 1993-02-02 Senju Pharmaceutical Co., Ltd. Controlled drug release composition
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
DK0669128T3 (da) 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
EP0779806B2 (de) * 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
EP0800385B1 (de) 1994-09-30 2000-12-20 Takeda Chemical Industries, Ltd. Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe

Also Published As

Publication number Publication date
EP0839525B1 (de) 2004-08-04
EP0839525A1 (de) 1998-05-06
JP4361144B2 (ja) 2009-11-11
JPH10182496A (ja) 1998-07-07
CA2219698A1 (en) 1998-04-30
CA2219698C (en) 2007-09-04
ATE272394T1 (de) 2004-08-15
US20020031545A1 (en) 2002-03-14
US6699500B2 (en) 2004-03-02
US6113943A (en) 2000-09-05
DE69730093T2 (de) 2006-07-20
DK0839525T3 (da) 2004-11-29
ES2221019T3 (es) 2004-12-16
PT839525E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DE69730093D1 (de) Zubereitung mit verzögerter Freisetzung
CY1117889T1 (el) Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου
NO973730D0 (no) Faste virkestofftilberedninger
NO884474L (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
NO913136D0 (no) Preparat for oeyedraaper.
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
DE69213183D1 (de) N'-Cyanomethylethylendiamin-N,N'-Diessigsäure, ihre Salze und ihre Herstellung
ATE83668T1 (de) Pflaster zur transdermalen anwendung.
NO880230D0 (no) Peroralt preparat med forsinket frigjoering.
IT1232917B (it) Procedimento per la fabbricazione di microsfere tramite reticolazionedi proteine, microsfere cosi' ottenute e loro impieghi
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
GB2341782A (en) Environmentally friendly chewing gum bases
IT8622780A0 (it) "2-cloro-12-(-3-dimetilammino-2-metilpropil)-12h-dibenzo-/d,g//1,3,6/d iossazocine otticamente attive eprocedimento per la loro preparazione.
IT1282289B1 (it) 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,
IT9021240A0 (it) Composti ad attivita' nootropa, procedimento per la loro preparazione e relative composizioni farmaceutiche
BE1002079A4 (fr) Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
FI902131A0 (fi) Kristallina mono- och kopolymerer av propylen i form av sfaeriska partiklar med hoeg porositet.
IT9022315A1 (it) Composti ad attivita' antiradicalica, procedimento per la loro prepara zione e loro impieghi.
RU96106995A (ru) Свечи с лидазой
ITMI912324A1 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT8847609A0 (it) -2-n-alchil,n-metlciclopropil-ammino-6,7 dimetossi tetraline, procedimento per la loro preparazione e composizioni farmaceutiche ad attivita' antiipertensiva che le contengono
IT1284850B1 (it) Procedimento per la preparazione di una composizione biocompatibile e osteogenica, e composizione cosi' ottenibile.
IT8847652A0 (it) Derivati della 2-ammino-6-7-dimetossi tetralina, procedimento per la loro preparazione e composizioni farmaceutiche ad attivita'antiipertensiva che le contengono.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8364 No opposition during term of opposition